Fig. 7From: Cross talk between acetylation and methylation regulators reveals histone modifier expression patterns posing prognostic and therapeutic implications on patients with colon cancerClinical significance and biological function of the histone modification score. A Kaplan–Meier curves of relapse-free survival (left) and overall survival (middle) in the meta-GEO cohort and of overall survival (right) in the TCGA-COAD cohort according to the HM_score. B–D Forest plots of the association between the HM_score value and relapse-free survival in a multivariate Cox analysis (B); forest plots of the association between HM_score value and overall survival in subgroups stratified by adjuvant chemotherapy conduction (C); forest plots of the benefits of adjuvant chemotherapy in the low- and high-HM_score groups in the meta-GEO and TCGA-COAD cohorts (D). Unadjusted hazard ratios (boxes) and 95% confidence intervals (horizontal lines) are depicted. E and F Boxplot of HM_score values among patients with different fluorouracil responses (E) and among patients with different CMS molecular subgroups (F) in the meta-GEO and TCGA-COAD cohorts. Boxes represent 25–75% of values, lines in boxes represent median values, whiskers represent 1.5 interquartile ranges, and black dots represent outliers. G and H Heatmaps of the correlation between the HM_score value, pathway activation (G), and tumor microenvironment cell infiltration (H) in the meta-GEO (upper) and TCGA-COAD (down) cohorts. *p < 0.05 and **p < 0.01. I Boxplot of the HM_score values among patients with different fluorouracil responses (left) and among patients with different CMS molecular subgroups (right) in the SYSUCC cohort. Boxes represent 25–75% of values, lines in boxes represent median values, whiskers represent 1.5 interquartile ranges, and black dots represent outliers. J and K Heatmaps of the correlation between HM_score value, pathway activation (J), and tumor microenvironment cell infiltration (K) in the SYSUCC cohort. RFS, relapse-free survival; OS, overall survival; CI, confidence interval; CMS, consensus molecular subtypes; R, response; NR, nonresponse; and ADJC, adjuvant chemotherapyBack to article page